NKp46 binding agents
US-12365731-B2 · Jul 22, 2025 · US
This page is not indexed by search engines while we improve data quality.
Blery Mathieu patents
Blery Mathieu is listed as an inventor on 35 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Blery Mathieu |
| Total patents | 35 |
| First publication | Dec 31, 2015 |
| Latest publication | Jul 22, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Treatment of peripheral t cell lymphoma
US-2024425586-A1 · Dec 26, 2024 · US
Treatment regimens using anti-nkg2a antibodies
US-2024368281-A1 · Nov 7, 2024 · US
Treatment regimens using anti-NKG2A antibodies
US-12037392-B2 · Jul 16, 2024 · US
Treatment of peripheral T cell lymphoma
US-11999784-B2 · Jun 4, 2024 · US
Novel stim1 splicing variants and uses thereof
US-2024083990-A1 · Mar 14, 2024 · US
Neutralization of inhibitory pathways in lymphocytes
US-2023303691-A1 · Sep 28, 2023 · US
Neutralization of inhibitory pathways in lymphocytes
US-2023235060-A1 · Jul 27, 2023 · US
Neutralization of inhibitory pathways in lymphocytes
US-11572410-B2 · Feb 7, 2023 · US
NKp46 BINDING AGENTS
US-2022340661-A1 · Oct 27, 2022 · US
Recent patents
Latest publications not already listed above.
NKp46 binding agents
US-11377492-B2 · Jul 5, 2022 · US
Treatment of cancers using anti-NKG2A agents
US-11225519-B2 · Jan 18, 2022 · US
Treatment regimens using anti-nkg2a antibodies
US-2021238285-A1 · Aug 5, 2021 · US
Neutralization of inhibitory pathways in lymphocytes
US-2021122821-A1 · Apr 29, 2021 · US
Neutralization of inhibitory pathways in lymphocytes
US-10870700-B2 · Dec 22, 2020 · US
Neutralization of inhibitory pathways in lymphocytes
US-2020332008-A1 · Oct 22, 2020 · US
Mica binding agents
US-2020299380-A1 · Sep 24, 2020 · US
Treatment regimens using anti-nkg2a antibodies
US-2020299383-A1 · Sep 24, 2020 · US
Neutralization of inhibitory pathways in lymphocytes
US-10711063-B2 · Jul 14, 2020 · US
Treatment regimens using anti-NKG2A antibodies
US-10676523-B2 · Jun 9, 2020 · US
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
US-2020023071-A1 · Jan 23, 2020 · US
NKp46 BINDING AGENTS
US-2019367609-A1 · Dec 5, 2019 · US
Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
US-10494433-B2 · Dec 3, 2019 · US
Treatment of cancers using anti-nkg2a agents
US-2019322744-A1 · Oct 24, 2019 · US
Treatment of peripheral t cell lymphoma
US-2019315857-A1 · Oct 17, 2019 · US
Treatment of peripheral T cell lymphoma
US-10344087-B2 · Jul 9, 2019 · US
Treatment of cancers using anti-NKG2A agents
US-10329348-B2 · Jun 25, 2019 · US
Neutralization of inhibitory pathways in lymphocytes
US-2019031755-A1 · Jan 31, 2019 · US
Treatment of cancers using anti-nkg2a agents
US-2017313773-A1 · Nov 2, 2017 · US
Treatment regimens using anti-nkg2a antibodies
US-2017298131-A1 · Oct 19, 2017 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Innate Pharma | 33 |
| Bristol Myers Squibb Co | 2 |
| Univ Brest Bretagne Occidentale | 1 |
| Inst Nat Sante Rech Med | 1 |
| Kalsiom | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| C07K16/2803 | 31 |
| A61P35/00 | 30 |
| C07K2317/24 | 29 |
| C07K2317/76 | 23 |
| C07K2317/732 | 22 |